145 related articles for article (PubMed ID: 28912877)
1. FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.
Zeng X; Che X; Liu YP; Qu XJ; Xu L; Zhao CY; Zheng CL; Hou KZ; Teng Y
Exp Ther Med; 2017 Oct; 14(4):3265-3272. PubMed ID: 28912877
[TBL] [Abstract][Full Text] [Related]
2. FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis.
Xu L; Shen JM; Qu JL; Song N; Che XF; Hou KZ; Shi J; Zhao L; Shi S; Liu YP; Qu XJ; Teng YE
Ann Transl Med; 2021 Feb; 9(3):258. PubMed ID: 33708885
[TBL] [Abstract][Full Text] [Related]
3. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
4. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.
Chong QY; You ML; Pandey V; Banerjee A; Chen YJ; Poh HM; Zhang M; Ma L; Zhu T; Basappa S; Liu L; Lobie PE
Oncotarget; 2017 Sep; 8(43):74188-74208. PubMed ID: 29088778
[TBL] [Abstract][Full Text] [Related]
5. Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression.
Zou J; Zhu L; Jiang X; Wang Y; Wang Y; Wang X; Chen B
Oncotarget; 2018 Feb; 9(13):11268-11278. PubMed ID: 29541412
[TBL] [Abstract][Full Text] [Related]
6. YY1 suppresses FEN1 over-expression and drug resistance in breast cancer.
Wang J; Zhou L; Li Z; Zhang T; Liu W; Liu Z; Yuan YC; Su F; Xu L; Wang Y; Zhou X; Xu H; Hua Y; Wang YJ; Zheng L; Teng YE; Shen B
BMC Cancer; 2015 Feb; 15():50. PubMed ID: 25885449
[TBL] [Abstract][Full Text] [Related]
7. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Wang Y; Li S; Zhu L; Zou J; Jiang X; Chen M; Chen B
Clin Transl Oncol; 2019 Aug; 21(8):1026-1033. PubMed ID: 30712236
[TBL] [Abstract][Full Text] [Related]
8. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth
Zeng X; Qu X; Zhao C; Xu L; Hou K; Liu Y; Zhang N; Feng J; Shi S; Zhang L; Xiao J; Guo Z; Teng Y; Che X
FASEB J; 2019 Oct; 33(10):10717-10730. PubMed ID: 31266372
[TBL] [Abstract][Full Text] [Related]
9. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
10. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
11. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
12. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer.
Xin X; Wen T; Gong LB; Deng MM; Hou KZ; Xu L; Shi S; Qu XJ; Liu YP; Che XF; Teng YE
Front Oncol; 2020; 10():425. PubMed ID: 32318339
[TBL] [Abstract][Full Text] [Related]
14. Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis.
Wang K; Xie C; Chen D
Int J Mol Med; 2014 May; 33(5):1268-74. PubMed ID: 24590400
[TBL] [Abstract][Full Text] [Related]
15. Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC‑7901 gastric cancer cells.
Xie C; Wang K; Chen D
Mol Med Rep; 2016 Jan; 13(1):386-92. PubMed ID: 26718738
[TBL] [Abstract][Full Text] [Related]
16. [RNPC1 induces sensitivity of HER-2-positive breast cancer BT474 cells to trastuzumab through upregulation of HER2].
Li CL; Zhou XJ; Lou PP; Xia TS; Shi L; Wang Y; Ding Q
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):172-8. PubMed ID: 26988821
[TBL] [Abstract][Full Text] [Related]
17. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
20. CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.
Wang Y; Yang YJ; Wang Z; Liao J; Liu M; Zhong XR; Zheng H; Wang YP
Oncol Lett; 2017 Sep; 14(3):2961-2969. PubMed ID: 28928834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
